Wedbush Rates IDEAYA Biosciences (IDYA) buy, $58 Price Target
Wedbush continues to support IDEAYA Biosciences with a buy rating and a target price of $58, a 85.54% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wedbush rated IDEAYA Biosciences, Inc. ($IDYA) "buy" with a $58 price target on June 12, 2026.
Since the rating, $IDYA is up 18.1% after 1 week, up 24.7% after 1 month and up 13.3% to date (from the $28.98 close on Jun 12, 2026).
IDYA
IDEAYA Biosciences, Inc.
Key Points
- On June 12, 2026, Wedbush reiterated its buy rating on IDEAYA Biosciences, Inc. (IDYA) with a price target of $58, while the stock closed at $31.26.
- Wedbush's $58 price target implies 85.54% upside from IDEAYA Biosciences, Inc.'s ($IDYA) current $31.26 share price.
- The stock trades significantly below its 52-week high of $42.68, suggesting potential for growth as it develops targeted cancer therapies.
- The consensus among analysts remains a strong buy, with a mean price target of about $52.38 based on 13 opinions.
Get $IDYA trade alerts by text
We text you when insiders, Congress or big funds trade $IDYA. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated IDEAYA Biosciences, Inc. alert may contain errors. Disclosures
Wedbush Sticks with Buy Rating on IDEAYA Biosciences
On June 12, 2026, Wedbush reiterated its buy rating on IDEAYA Biosciences, Inc. (IDYA) with a price target of $58. The stock closed at $31.26, showing a significant gap between the current price and the target set by the analyst Robert Driscoll.
IDEAYA's Position in the Market
This reiteration comes as IDEAYA continues to advance its pipeline of targeted therapies for cancer. The company, based in South San Francisco, focuses on precision medicine and has several promising candidates in clinical trials, including Darovasertib for uveal melanoma and IDE849 for small cell lung cancer. The company is navigating a competitive biotechnology landscape, and maintaining a strong buy rating from Wedbush reflects confidence in its growth potential.
Analysts Set New Price Targets
The sentiment from other analysts also supports a positive outlook for IDEAYA. On October 16, 2026, William Blair initiated coverage with an outperform rating. Stifel initiated with a buy rating on October 14, setting a target of $48. Guggenheim maintained a buy rating on September 9, raising its target to $57 from $54. Meanwhile, Citizens reiterated a market outperform rating on September 1 with a target of $42. Truist Securities has also been bullish, maintaining a buy rating with a target of $59.
Stock Performance Insights
IDYA's shares have experienced fluctuations, trading well below its 52-week high of $42.68 and near its 52-week low of $25.36. This current trading range may indicate an opportunity for investors looking for growth as IDEAYA continues its clinical trials and partnerships in the oncology space.
$IDYA price target
IDEAYA Biosciences, Inc. daily closes and this analyst's $58 target. Not advice.
What IDEAYA Biosciences, Inc. Does
IDEAYA Biosciences, Inc. develops targeted cancer therapies using molecular diagnostics. The company is actively involved in several clinical trials and has formed strategic alliances with major pharmaceutical companies, which could enhance its market position and drive future growth.
What's Ahead for IDEAYA Biosciences, Inc.
Investors will be watching for IDEAYA's next earnings report, scheduled for November 9, 2026. As a reminder, Wedbush's rating reflects positions as of the reporting date and may not represent current market conditions. The continued support from analysts suggests optimism about the company's future prospects as it progresses with its innovative therapies.
Related Filing Alerts
Source: Wedbush's rating change on $IDYA (Jun 12, 2026). Written by software, not financial advice. How we make alerts